Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Makoto Takeda and Takaji Wakita.
Makoto Takeda
Connection Strength
0.809
Takaji Wakita
  1. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience. 2021 Apr 23; 24(4):102367.
    View in: PubMed
    Score: 0.234
  2. Corrigendum to: Environmental Sampling for Severe Acute Respiratory Syndrome Coronavirus 2 During a COVID-19 Outbreak on the Diamond Princess Cruise Ship. J Infect Dis. 2021 02 13; 223(3):540.
    View in: PubMed
    Score: 0.232
  3. Environmental Sampling for Severe Acute Respiratory Syndrome Coronavirus 2 During a COVID-19 Outbreak on the Diamond Princess Cruise Ship. J Infect Dis. 2020 09 01; 222(7):1098-1102.
    View in: PubMed
    Score: 0.225
  4. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. Front Microbiol. 2021; 12:651403.
    View in: PubMed
    Score: 0.059
  5. Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro. Int J Mol Sci. 2021 Mar 19; 22(6).
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.